AstraZeneca's Immune-Oncology Strategy Suffers Setback
This article was originally published in Scrip
AstraZeneca Plc's strategy of pushing the development combination therapies to offset its relatively tardy start in immune-oncology has suffered a setback. It has suspended recruitment into two trials which are testing the effectiveness of a combination of AZD9291 and durvalumab (MEDI4736) in non-small cell lung cancer (NSCLC) following an increased incidence of lung disease. Durvalumab is in a number of trials with external collaborators which will be following this development closely. Meanwhile, Clovis Oncology Inc., which has a competitor product to AZD9291 – rociletinib – will also be a keen observer. Both products are due to be filed as monotherapies next year.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.